The clinical and genetic Spectrum of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI) in the Eastern Province of Saudi Arabia

被引:14
作者
Al-Sannaa N.A. [1 ]
Al-Abdulwahed H.Y. [1 ]
Al-Majed S.I. [1 ]
Bouholaigah I.H. [1 ]
机构
[1] Pediatrics Service Division, Johns Hopkins Aramco Healthcare, Saudi Aramco, Dhahran
关键词
Maroteaux-Lamy Syndrome; Unrelated Consanguineous Families; Autosomal Recessive Lysosomal Storage Disease; First-cousin Parents; arsB Gene;
D O I
10.1007/s12687-017-0329-1
中图分类号
学科分类号
摘要
Mucopolysaccharidosis (MPS VI) or Maroteaux-Lamy syndrome is an autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine 4-sulfatase or arylsulfatase B. It is involved in the degradation of glycosaminoglycans and characterized by a wide spectrum of clinical and genetic heterogeneity. So far, more than 150 mutations have been reported in the ARSB gene. Most of these mutations are either novel, private, or compound heterozygous making phenotype–genotype correlation as well as population screening difficult. The aim of our study is to determine the genotypes and phenotypes of MPS VI among the Saudi population at the Eastern Province of Saudi Arabia. The clinical data of all the patients seen and diagnosed with MPS VI (Maroteaux-Lamy syndrome) at the main hospital from January 1, 1983, to December 31, 2016, were reviewed. A total of 18 patients from 6 unrelated consanguineous families (first-cousin parents) were diagnosed with MPS VI during the defined 33 years. All of the affected patients displayed the severe phenotype of MPS VI. Only one genotype (c.753C > Gp.Y251X) was identified among five of the studied families. All of those families were inhabitants of Al-Hofuf area, but they descended from different clans. A second genotype (c270_274del5bp pc.91Afs*34) was detected in a single family who had originated from Abha area (the southern-west region of the country). This report demonstrated the homogeneity for both phenotype and genotype of our studied patients with MPS VI. This may eventually make selective asymptomatic carrier test and newborn screening highly feasible in this region of country. © 2017, Springer-Verlag GmbH Germany.
引用
收藏
页码:65 / 70
页数:5
相关论文
共 16 条
[1]  
Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., Et al., Cumulative incidence rates of the mucopolysaccharidoses in Germany, J Inherit Metab Dis, 28, pp. 1011-1017, (2005)
[2]  
Costa-Motta F.M., Bender F., Acosta A., Abe-Sandes K., Machado T., Bomfim T., Boa Sorte T., da Silva D., Bittles A., Giugliani R., Leistner-Segal S., A community-based study of mucopolysaccharidosis type VI in Brazil: the influence of founder effect, endogamy and consanguinity, Hum Hered, 77, 1-4, pp. 189-196, (2014)
[3]  
Giugliani R., Harmatz P., Wraith J.E., Management guidelines for mucopolysaccharidosis VI, Pediatrics, 120, 2, pp. 405-418, (2007)
[4]  
Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Et al., Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study, J Pediatr, 148, pp. 533-539, (2006)
[5]  
Harmatz P., Giugliani R., Schwartz I.V., Guffon N., Teles E.L., Miranda M.C., Et al., Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human Nacetylgalactosamine 4-sulfatase, Mol Genet Metab, 94, pp. 469-475, (2008)
[6]  
el-Hazmi M.A., al-Swailem A.R., Warsy A.S., al-Swailem A.M., Sulaimani R., al-Meshari A.A., Consanguinity among the Saudi Arabian population, J Med Genet, 32, 8, pp. 623-626, (1995)
[7]  
Herskhovitz E., Young E., Rainer J., Hall C.M., Lidchi V., Chong K., Vellodi A., Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up, J Inherit Metab Dis, 22, 1, pp. 50-62, (1999)
[8]  
Jurecka A., Zakharova E., Cimbalistiene L., Gusina N., Kulpanovich A., Golda A., Opoka-Winiarska V., Piotrowska E., Voskoboeva E., Tylki-Szymanska A., Mucopolysaccharidosis type VI: a predominantly cardiac phenotype associated with homozygosity for p.R152W mutation in the ARSB gene, Am J Med Genet A, 161A, 6, pp. 1291-1299, (2013)
[9]  
Karageorgos L., Brooks D.A., Pollard A., Melville E.L., Hein L.K., Clements P.R., Ketteridge D., Swiedler S.J., Beck M., Giugliani R., Harmatz P., Wraith J.E., Guffon N., Leao Teles E., Sa Miranda M.C., Hopwood J.J., Mutational analysis of 105 mucopolysaccharidosis type VI patients, Hum Mutat, 28, 9, pp. 897-903, (2007)
[10]  
Malm G., Lund A.M., Mansson J.E., Heiberg A., Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence, Acta Paediatr, 97, pp. 1577-1581, (2008)